Building on these observations, we performed in vivo experiments involving tail vein injections of exogenous CFSE-labeled mast cells to verify with low BTG2 expression exhibited stronger migratory ability toward tumor sites and their draining lymph nodes (Figure 3C; Supplementary Figure S3A). The gene discussed is BTG2; the disease is neoplasm.